Table 5.
Correlation between BRCA mutation status and prognostic markers/tumor histopathology
| BRCA1 carriers, n (%) | BRCA2 carriers, n (%) | Noncarriers, n (%) | n (%) | P-value | |
|---|---|---|---|---|---|
|
| |||||
| Cancer of breast/breast and ovary (n=131)a | |||||
|
| |||||
| Prognostic markers | (n=24) | (n=7) | (n=100) | (n=131) | |
|
| |||||
| ER | 7 (29.2) | 2 (28.6) | 43 (43.0) | 52 (39.7) | 0.43 |
| Positive | 17 (70.8) | 5 (71.4) | 57 (57.0) | 79 (60.3) | |
| Negative | |||||
|
| |||||
| PR | 6 (25.0) | 2 (28.6) | 34 (34.0) | 42 (32.1) | 0.74 |
| Positive | 18 (75.0) | 5 (71.4) | 66 (66.0) | 89 (67.9) | |
| Negative | |||||
|
| |||||
| HER2/neu | 2 (8.3) | 3 (42.9) | 11 (11.0) | 16 (12.2) | 0.07 |
| Positive | 22 (91.7) | 4 (57.1) | 89 (89.0) | 115 (87.8) | |
| Negative | |||||
|
| |||||
| Subtypes | 0 (0.0) | 0 (0.0) | 5 (5.0) | 5 (3.8) | 0.08 |
| HR+b, HER2/neu+ | 7 (29.2) | 2 (28.6) | 38 (38.0) | 47 (35.9) | |
| HR+b, HER2/neu− | 15 (62.5) | 2 (28.6) | 52 (52.0) | 69 (52.7) | |
| ER– PR– HER2− (TNBC) | 2 (8.3) | 3 (42.9) | 5 (5.0) | 10 (7.6) | |
| ER– PR– HER2+ (HER2 enriched) | |||||
|
| |||||
| Cancer of ovary/breast and ovary (n=80) | |||||
| Tumor histopathology | (n=25) | (n=10) | (n=45) | (n=80) | |
| Serous carcinoma (HG) | 25 (100) | 9 (90.0) | 42 (93.3) | 76 (95.0) | 0.29 |
| Endometrioid carcinoma (HG) | 0 (0.0) | 0 (0.0) | 1 (2.2) | 1 (1.3) | |
| Endometrioid carcinoma (LG) | 0 (0.0) | 0 (0.0) | 2 (4.4) | 2 (2.5) | |
| Clear cell carcinoma | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (1.3) | |
Notes:
a
One breast cancer subject positive for a mutation in both BRCA1 and BRCA2 genes was excluded from this comparison.
b
HR+ include ER− and/or PR-positive subjects. Column percentage is shown in parentheses.
Abbreviations: ER, estrogen receptor; HG, high grade; LG, low grade; PR, progesterone receptor.